BridgeBio Pharma

Yahoo Finance • 5 days ago

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index adding 0.1% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 days ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

Health care stocks advanced Thursday afternoon, with the NYSE Health Care Index adding 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 5 days ago

Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Stifel upgraded Texas Instruments (TXN... Full story

Yahoo Finance • 14 days ago

Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, reiterating an Outperform rating on the... Full story

Yahoo Finance • 17 days ago

Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative?

BridgeBio Pharma has announced that long-term efficacy and safety data from the open-label extension of its Phase 3 ATTRibute-CM trial of transthyretin stabilizer acoramidis in ATTR-CM, along with three supporting posters and real-world su... Full story

Yahoo Finance • last month

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

-Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early separation from placeb... Full story

Yahoo Finance • last month

Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Rivian (RIVN) to Buy f... Full story

Yahoo Finance • last month

Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the 10 Fastest Growing NASDAQ Stocks to Buy.Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating On February 25, 2026, Truist analyst Danielle Bril... Full story

Yahoo Finance • last month

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that addition... Full story

Yahoo Finance • 2 months ago

BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth

Earnings Call Insights: BridgeBio Pharma, Inc. (BBIO) Q4 2025 MANAGEMENT VIEW * CEO Neil Kumar described the quarter as a transformative inflection point, stating, "This company will turn from a cash consumptive business to one that ge... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma GAAP EPS of -$1.00 misses by $0.33, revenue of $154.2M beats by $5.13M

* BridgeBio Pharma press release [https://seekingalpha.com/pr/20411990-bridgebio-reports-fourth-quarter-and-full-year-2025-financial-results-and-commercial-updates] (BBIO [https://seekingalpha.com/symbol/BBIO]): Q4 GAAP EPS of -$1.00 mis... Full story

Yahoo Finance • 2 months ago

BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.BoFA Notes BridgeBio Pharma, Inc. (BBIO)'s Upcoming Q4 Earnings May Have Limited Market Impact BridgeBio Pharma, Inc. (NASDAQ:B... Full story

Yahoo Finance • 2 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on Februa... Full story

Yahoo Finance • 2 months ago

Tyra Biosciences price target raised to $53 from $37 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform rating on the shares. The firm notes BridgeBio (BBIO) announced positive topline Phase 3 data for infigratini... Full story

Yahoo Finance • 2 months ago

BridgeBio rises after late-stage trial win for dwarfism therapy

[Achondroplasia] Hailshadow BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]) added ~13% in the premarket on Thursday after the company reported success in a pivotal Phase 3 trial for infigratinib, its experimental therapy fo... Full story

Yahoo Finance • 4 months ago

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story

Yahoo Finance • 4 months ago

PayPal downgraded, Roku upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Roku (ROKU) to Buy... Full story

Yahoo Finance • 4 months ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: American Eagle Outfitters, Ferrari, Intuitive Surgical, Roku, PayPal, Synopsis, Visa, and More

Chaay_Tee / iStock via Getty Images Quick Read As expected, the Federal Reserve cut the Funds rate 25 basis points on Wednesday. The rate cut lowered the Fed funds rate to 3.50%-3.75%, the lowest since the post-pandemic era in 2022. Rate... Full story

Yahoo Finance • 5 months ago

BridgeBio to Participate in December Investor Conferences

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its managemen... Full story

Yahoo Finance • 5 months ago

Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?

24/7 Wall St. Quick Read Alphabet (GOOG,GOOGL) holds a portfolio of 37 stocks worth $2.5B to $3B through its venture arms GV and CapitalG. Google’s portfolio is heavily tilted toward healthcare and biotech with its largest holding being... Full story